TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary Aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resolution of choledocholithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Hour 0 to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Rating Scale for Tremor (CRST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Safety as determined by reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of lesions with semiological characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brachial artery function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence Based on AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence Based on AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Quetiapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Calculated to the Last Observable Concentration at Time t (AUCt) for Quetiapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC∞) for Quetiapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrosis and inflammation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of COX-2 inhibitors prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of omeprazole prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: STH transmission interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Weight of Testicular Tissue Retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force needed for cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal Bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peri-implant crevicular fluid cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GI-2 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amount of analgetics used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference of perfusion after smoking/vaping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain on mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point-prevalence abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of oscillatory response patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial/temporal coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Incident Diabetes-related ED Visits and/or Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Retinal vascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of Endometrial Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Diabetic ketoacidosis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tmax - the time of occurrence of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - the area under the plasma concentration versus time curve from time zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ALSFRS-R Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety severity (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety diagnostic status (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise frequency (change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who do Not Require a Platelet Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects maintaining mean Hb ≥ 11.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety related to Electrochemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of prolonged air leaks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in airway cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spirometry-FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: chest compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: chest compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hands-off time of chest compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: safety of intrauterine application of Intercoat
Endpoint domain: Adverse events/effects
Primary endpoint: Major cardiovascular adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Acute Migraine Management Strategies: Treat Early
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Acute Migraine Management Strategies: Overuse
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Preventive Behavioral Strategies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Validation with gold-standard polysomnography (PSG) recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Failure-free survival at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Maximum plasma concentration of JNJ 39393406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum plasma concentration of JNJ 39393406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of JNJ-39393406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of autistic participants with autoimmune markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With the Presence of Microorganisms 3 Days After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: crestal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Migraine Headache Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiogenic potential of proangiogenic immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: homeostatic model assessment (HOMA) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appetite hormone (ghrelin [pg/ml])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appetite hormone (leptin [ng/ml])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood loss reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of biliary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial increase in intact Proinsulin levels (Peak, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial Proinsulin/Insulin Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients with Malgylcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients that contract an infection
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax - Maximum Observed Concentration - Carvedilol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Carvedilol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Carvedilol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy rate after percutaneous renal cryoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Non-alcoholic Fatty Liver Disease Ultrasonography Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient's assessment of overall pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pain (Characteristic pain intensity scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pain (Pain Pressure Threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial domain positive change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Motor development at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe postoperative rebound pain
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Depression Rating Scale (17 item version)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentrations of total methylphenidate HCl and its major metabolite (PPAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Assessment Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Developmental Impact
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Adherence to each intervention component
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Survivorship analysis of the P.F.C. fixed bearing knee system
Endpoint domain: Mortality/survival
Primary endpoint: Global ventilation heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local ventilation heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in number of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in size of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in size of desmoid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Infusion related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Measured GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of placental retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bone remodeling: horizontal measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone remodeling: vertical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue profiles measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain level measured by NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Blood Culture for L Reuteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to the procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Grade 3-4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of grade 3-4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 30-day incidence of composite outcome (MACE-5)
Endpoint domain: Mortality/survival
Primary endpoint: GVHD/Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Within-individual mammographic density (MD) longitudinal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Effectiveness of drug-eluting bead trans-arterial chemo-embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Profiles of body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Profiles of pro inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Free Survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: correlation between SUV and clinical evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demoralization Scale-Mandarin Version (DS-MV) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Maximal Change in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in signs and symptoms composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with undetectable plasma HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute difference in hepatopulmonary shunt fraction values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients chronically relieved from mitral valve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of mitral valve regurgitation in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful day case
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe day case
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who agree to referral
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Diversity index of oronasal fungal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of the oronasal fungal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom severity and interference with function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Platelets function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In vitro vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of tooth decay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity measured by neutralization test and ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of epidural analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Danazol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cytokines associated with SARS CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achievement of goal blood pressure response defined by a mean sitting diastolic blood pressure <90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean sitting diastolic blood pressure during each visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean sitting systolic blood pressure during each visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Postoperative hemorrhagia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Biliary fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Stretched penile length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Yale Preoperative Anxiety Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Pain Scale (VAS) 24 Hour After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate in the General Clinical Research Unit (GCRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of depression and mania
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % women who attend cervical screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal environment health check
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF-EF questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Ploidy state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Objective Manifestations and Subjective New or Increased Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of OR admission delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with highly expressed serum miRNA30-a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ALSFRS-R Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant neonatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Lower Urinary Tract Dysfunction symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline Post Surgery (Oswestry Disability Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with Adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in cerebral oxygen saturation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes